Page 6 - David Bartel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Handelsbanken Fonder AB grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 50.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 192,294 shares of the biopharmaceutical company’s stock after acquiring an additional 64,701 shares during the quarter. Handelsbanken Fonder AB’s […]

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) and Sernova (OTCMKTS:SEOVF – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Profitability This table compares Alnylam Pharmaceuticals and Sernova’s net margins, return […]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) EVP Indrani Lall Franchini sold 3,500 shares of the business’s stock in a transaction on Thursday, April 6th. The stock was sold at an average price of $210.00, for a total value of $735,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which […]

China Universal Asset Management Co. Ltd. raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 1,110.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,604 shares of the biopharmaceutical company’s stock after purchasing an additional 12,480 shares […]

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its target price increased by Morgan Stanley from $205.00 to $210.00 in a research report released on Tuesday, Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on the company. JPMorgan Chase […]